Dose Finding Studies for Therapies with Late-Onset Toxicities: A Comparison Study of Designs
Helen Barnett, Oliver Boix, Dimintris Kontos, Thomas Jaki

TL;DR
This study compares eight methods for phase I dose-finding trials that incorporate late-onset toxicities without significantly extending trial duration, highlighting the superior performance of model-based approaches like Interval Censored and Time-to-Event CRM.
Contribution
It introduces and evaluates methods that include late-onset toxicity data in dose-finding trials without prolonging the trial, providing practical recommendations.
Findings
Model-based approaches outperform model-assisted methods.
Interval Censored and Time-to-Event CRM are most effective.
Recommended methods balance accuracy and trial duration.
Abstract
An objective of phase I dose-finding trials is to find the maximum tolerated dose; the dose with a particular risk of toxicity. Frequently, this risk is assessed across the first cycle of therapy. However, in oncology, a course of treatment frequently consists of multiple cycles of therapy. In many cases, the overall risk of toxicity for a given treatment is not fully encapsulated by observations from the first cycle, and hence it is advantageous to include toxicity outcomes from later cycles in phase I trials. Extending the follow up period in a trial naturally extends the total length of the trial which is undesirable. We present a comparison of eight methods that incorporate late onset toxicities whilst not extensively extending the trial length. We conduct simulation studies over a number of scenarios and in two settings; the first setting with minimal stopping rules and the second…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsStatistical Methods in Clinical Trials · Health Systems, Economic Evaluations, Quality of Life · Innovative Microfluidic and Catalytic Techniques Innovation
